Logo

Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-09) Trial for Stage IB-IIIA NSCLC Regardless of PD-L1 Expression at ESMO 2022

Share this

Merck Presents Results of Keytruda (pembrolizumab) in P-III (KEYNOTE-09) Trial for Stage IB-IIIA NSCLC Regardless of PD-L1 Expression at ESMO 2022

Shots:

  • The P-III (KEYNOTE-091/EORTC-1416-LCG/ETOP-8-15 – PEARLS) trial evaluates Keytruda (200mg, IV, q3w) for 1yr. vs PBO in a ratio (1:1) in 1177 patients with stage IB to IIIA NSCLC following surgical resection regardless of PD-L1 expression
  • The results showed an improvement in DFS with a 24% reduction in risk of disease recurrence or death, m-DFS (53.6mos. vs 42.0mos.) while a favorable trend in OS was identified & did not reach statistical significance at an interim analysis. The safety profile was consistent with that observed in previously reported studies
  • The results will be shared with regulatory authorities globally. The company has an extensive clinical development program in lung cancer
Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions